Evidence map›Paper›PMID 41796348›Full record

ReviewCancer cell international2026

Harnessing the LncRNA CCAT2 role in gastric cancer: from molecular insights to clinical implications.

Amin Behzadnia, Ahmad Ghorbani Vanan, Kamyar Bagheri, Farid Ghorbaninezhad, Fatemeh Ghadyani, Mohammadreza Dashti, Mahfam Edrisian, Narges Hedayatian, Safa Tahmasebi, Elham Safarzadeh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amin Behzadnia *Department of Medical Engineering, South Tehran Branch, Islamic Azad University, Tehran, Iran.
Ahmad Ghorbani Vanan *Student Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Kamyar Bagheri *Student Research Committee, Abadan University of Medical Sciences, Abadan, Iran.
Farid Ghorbaninezhad *Student Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fatemeh GhadyaniStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammadreza DashtiStudent Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahfam EdrisianStudent Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Narges HedayatianDepartment of Genetics, Islamic Azad University Zanjan, Zanjan, Iran.
Safa TahmasebiStudent Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. safa.tahmasebi@sbmu.ac.ir.
Elham SafarzadehCancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran. Elham.im63@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a critical global health issue due to its high morbidity and mortality rate. Gastric cancer is among the five most frequently diagnosed cancers and is the third leading cause of cancer-related death. Risk factors include Helicobacter pylori infection, poor diet, tobacco use, and inherited susceptibility. Diagnosis often involves endoscopy and biopsy, and treatment options include surgery and chemotherapy. Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer biology. Colon cancer-associated transcript 2 (CCAT2) has been identified as a key factor in the development and progression of gastric cancer. CCAT2 is expressed at higher levels in gastric tumor tissues compared with normal tissues and is linked to poor prognosis, lymph node metastasis, and advanced tumor stages. Functional studies suggest that CCAT2 promotes cancer cell migration of cancer cells, epithelial-mesenchymal transition (EMT), and invasion through key regulatory pathways including PI3K/mTOR. This review aims to discuss how lncRNA CCAT2 contributes to gastric cancer growth and to evaluate its potential as both a diagnostic and prognostic biomarker, which may support the development of new therapeutic strategies and improve patient outcomes.

Indexed as

BiomarkerCCAT2DiagnosisGastric cancerLncRNAPrognosis

Identifiers

PMID41796348
PMCPMC13081384

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.